SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
----------------------------------
Date of report (Date of earliest event reported):
September 15, 2004 (September 14, 2004)
---------------------------------------
DOV Pharmaceutical, Inc.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
Delaware 000-49730 22-3374365
(State or other jurisdiction (Commission file number) (IRS employer
of incorporation) identification no.)
433 Hackensack Avenue, Hackensack, NJ 07601
(Address of principal executive offices) (Zip code)
- --------------------------------------------------------------------------------
(201) 968-0980
(Registrant's telephone number, including area code)
Item 9.01 Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits. The following exhibit is furnished herewith:
Exhibit
Number Title
- ------ -----
99.1 Press release dated September 14, 2004, issued by registrant
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DOV Pharmaceutical, Inc.
Date: September 15, 2004 /s/ Arnold Lippa
----------------------------------------
Arnold Lippa
Chief Executive Officer
EXHIBIT INDEX
Exhibit
Number Title
- ------ -----
99.1 Press release dated September 14, 2004, issued by registrant